Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
25 Octobre 2022 - 4:00PM
Business Wire
Community Routes: Access to Mental Healthcare,
a partnership between Direct Relief, the National Association of
Free and Charitable Clinics, and Teva Pharmaceuticals, provides
awards to support clinics expanding access to mental health
services across three states
Teva Pharmaceuticals, the National Association of Free and
Charitable Clinics (NAFC) and Direct Relief announced today – as
part of a two-year, $2 million commitment – the awarding of
$825,000 in grant funding for 11 free and charitable clinics
addressing mental health across Florida, New Jersey and
California.
The grant awardees were selected for their innovative and
practical approaches to mental health care, which include efforts
to expand healthcare access for underserved and vulnerable patients
experiencing mental and behavioral health issues, with a focus on
depression and anxiety.
“The free and charitable clinics chosen for this initiative are
already providing outstanding care in their communities, and this
funding, generously provided by Teva, will allow them to do even
more, by expanding life-saving mental health care to those who need
it most,” said Thomas Tighe, CEO and President of Direct
Relief.
In addition to funding, Teva is making a broad portfolio of
generic mental health medications available on a charitable
basis.
”Teva is proud to partner with Direct Relief and the National
Association of Free and Charitable Clinics on Community Routes:
Access to Mental Health Care, a novel health equity initiative
aiming to expand access to healthcare services for underserved
populations,” added Dr. Sven Dethlefs, Executive Vice President,
North America Commercial. “At Teva, we know how critical it is to
enable access to medicines that help improve people’s lives and
look forward to seeing how these local clinics create or expand
needed programs that drive real impact for patients.”
Anxiety and depression disorders affect more than 40 million
adults in the U.S. annually. Additionally, 84 percent of physicians
reported an increase in new diagnoses of mental health conditions
since the pandemic began, especially among racial and ethnic
minorities and lower-income households, according to a recent
nationwide survey by the Morehouse School of Medicine and Teva
Pharmaceuticals.
“Through this program, clinics will be able to enhance and
expand access to crucial mental health services for their
communities,” said Nicole Lamoureux, President and CEO of NAFC.
“The NAFC is grateful that Direct Relief and Teva Pharmaceuticals
not only recognize the barriers to care communities often face and
the importance of mental health care, but that they also are taking
steps to join with the NAFC and support our clinics on the ground
to provide solutions and increased access to care.”
The 2022 winners are:
FLORIDA
- University of Florida Mobile Outreach in Gainesville,
Florida - Creates and disseminates evidence-informed, easily
accessible mental health wellness curriculum to underserved
populations via trusted community members through a mobile outreach
model.
- Grace Medical Home in Orlando, Florida - Expands an
existing program that proactively identifies trauma and offers
individualized interventions through an integrated, whole-person,
multi-disciplinary approach to improve health outcomes.
- Talbot House Ministries of Lakeland, Inc., in Lakeland,
Florida - Supports medication reconciliation services provided
through the pharmacy, outreach and event coordination, and outreach
to homeless encampments to connect with clinical services and
referrals for mental health care, patient transportation, and
education.
NEW JERSEY
- Cape Volunteers in Medicine in Cape May Court House, New
Jersey - Improves mental and behavioral health access and
treatment among at-risk populations by expanding depression and
anxiety screenings. Funding will also support community events to
identify community members' mental and physical needs.
- Bergen Volunteer Medical Initiative, Inc., in Hackensack,
New Jersey - Increases capacity and fills a much-needed gap in
care for Spanish-speaking patients with depression and anxiety
through the support of a bilingual mental health practitioner.
- Parker Family Health Center in Red Bank, New Jersey -
Supports a collaboration with the Mental Health Association of
Monmouth County, which allows for a bilingual therapist to offer
weekly counseling and the creation of mental health education to be
shared at live community events, virtually, and digitally.
CALIFORNIA
- Samaritan House in San Mateo, California - Samaritan
House in San Mateo, California - Expands existing mental health
services to include a traineeship program for students pursuing
advanced degrees in marriage and family therapy or social work. The
program also aims to strengthen collaboration with community
organizations that provide more specialized care, develop
educational resources, and offer comprehensive services to patients
with depression and anxiety.
- Symba Center in Apple Valley, California - Supports
successful, trauma-informed, mental and behavioral health care at a
homeless shelter site.
- Westminster Free Clinic in Thousand Oaks, California -
Offers a range of mental health services, including individual and
peer support, and a training program that empowers parents to
identify the early signs of mental health issues.
- Lestonnac Free Clinic in Orange, California - Supports a
licensed clinical social worker and programs to provide care
through a trauma-informed lens, who will also supervise and mentor
interns from local colleges and universities.
- Savie Health in Lompoc, California - Provides culturally
sensitive resources and referrals to help patients overcome
barriers to mental health care through bilingual community health
workers.
About Direct Relief A humanitarian organization committed
to improving the health and lives of people affected by poverty and
emergencies, Direct Relief delivers lifesaving medical resources
throughout the U.S. and world to communities in need—without regard
to politics, religion, or ability to pay. For more information,
visit https://www.DirectRelief.org.
About National Association of Free and Charitable Clinics
National Association of Free and Charitable Clinics (NAFC) is the
only nonprofit 501c (3) organization whose mission is solely
focused on the issues and needs of the medically underserved
throughout the nation and the more than 1,400 Free and Charitable
Clinics that serve them. The NAFC has earned the Platinum Seal of
Transparency from GuideStar and a 4-star rating from Charity
Navigator. Founded in 2001 and headquartered near Washington, D.C.,
the NAFC is working to ensure that the medically underserved have
access to affordable quality health care and strives to be a
national voice promoting quality health care for all. For more
information about the NAFC, please visit www.nafcclinics.org.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve
people’s lives for more than a century. We are a global leader in
generic, biosimilar and specialty medicines with a portfolio
consisting of over 3,500 products in nearly every therapeutic area.
Around 200 million people around the world take a Teva medicine
every day, and are served by one of the largest and most complex
supply chains in the pharmaceutical industry. Along with our
established presence in generics, we have significant innovative
research and operations supporting our growing portfolio of
specialty and biopharmaceutical products. Learn more at
www.tevapharm.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
which are based on Teva’s management current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to: our ability to impact and
effectively execute on our social, economic, environment and
governance related strategies and goals; our ability to satisfy the
targets set forth in our sustainability-linked senior notes and in
other sustainability-linked financing instruments that we may
issue; and the impact of ESG issues on our business; our ability to
successfully compete in the marketplace, including: that we are
substantially dependent on our generic products; our substantial
indebtedness; our business and operations in general, including:
uncertainty regarding the COVID-19 pandemic and the governmental
and societal responses thereto, costs and delays resulting from the
extensive pharmaceutical regulation to which we are subject or
delays in governmental processing time due to travel and work
restrictions caused by the COVID-19 pandemic, the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; compliance, regulatory and
litigation matters, including: failure to comply with complex legal
and regulatory environments, increased legal and regulatory action
in connection with public concern over the abuse of opioid
medications and our ability to reach a final resolution of the
remaining opioid-related litigation; scrutiny from competition and
pricing authorities around the world, including our ability to
successfully defend against the U.S. Department of Justice criminal
charges of Sherman Act violations; potential liability for patent
infringement; product liability claims; failure to comply with
complex Medicare and Medicaid reporting and payment obligations;
and compliance with anti-corruption sanctions and trade control
laws; other financial and economic risks; and other factors
discussed in our Quarterly Report on Form 10-Q for the second
quarter of 2022 and in our Annual Report on Form 10-K for the year
ended December 31, 2021, including in the sections captioned “Risk
Factors” and “Forward-Looking Statements” and in our other reports
that we file with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221025005251/en/
For More Information, Contact: Direct Relief: Tony Morain –
TMorain@directrelief.org NAFC: Kerry Thompson –
kerry@nafcclinics.org Teva: Yonatan Beker –
Yonatan.Beker@tevapharm.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2023 à Août 2024